home / stock / abvc / abvc news

ABVC News and Press, ABVC BioPharma Inc. From 10/08/25

Stock Information
Company Name: ABVC BioPharma Inc.
Stock Symbol: ABVC
Market: NASDAQ
Website: abvcpharma.com
Menu
ABVC ABVC Quote ABVC Short ABVC News ABVC Articles ABVC Message Board
Get ABVC Alerts

News, Short Squeeze, Breakout and More Instantly...
ABVC - ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production

SILICON VALLEY, CA - October 8, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a  US$70,000 licensing payment  from its partner,  ForSeeCon Eye Corporation (“ForSee...
ABVC - ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model

SILICON VALLEY, CA - September 19, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. . (NASDAQ: ABVC) (“ABVC” or the “Company”) today announced that it has received a licensing payment of US$145,950 from OncoX BioPharma, Inc. (“OncoX”) under the terms of...

ABVC - ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025

SILICON VALLEY, CA - August 29, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CNS) disord...

ABVC - BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration

Silicon Valley, CA - ( NewMediaWire ) - August 27, 2025 -   ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced that one of its ...
ABVC - ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025

SILICON VALLEY, CA - August 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC)  ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced its financi...

ABVC - Expected US Company Earnings on Wednesday, August 13th, 2025

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

ABVC - Expected earnings - ABVC BioPharma Inc.

ABVC BioPharma Inc. (ABVC) is expected to report for Q2 2025
ABVC - BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts

ABVC’s 28,000 sq ft Silicon Valley Manufacturing Facility Stands Ready as Global Supply Chains Realign and Trust-based Localization Becomes Key SILICON VALLEY, CA - August 8, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceuti...

ABVC - ABVC BioPharma Gains Confidence From International Investors to Support Growth Path

SILICON VALLEY, CA - August 6, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, is pleased to share that it has rece...

ABVC - OncoX Deepens ABVC Alliance

CEO Yen Wen Pin’s IPO Vision Gains Traction as OncoX Expands Pipeline SILICON VALLEY, CA - August 1, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (cent...
Previous 10 Next 10